脾脏大小与脾切除术对骨髓纤维化异基因造血细胞移植结局的影响:EBMT回顾性分析
该研究基于EBMT注册组1195例2000-2017年间接受氟达拉滨-白消安或氟达拉滨-美法仑方案移植的骨髓纤维化患者,分析脾脏大小和脾切除术对移植结局的影响。多因素分析显示脾切除术与较低的非复发死亡率相关,但增加复发风险,对总生存无显著影响;在进展性疾病患者中,脾切除术相比可触及脾长度≥15cm者生存改善。
要点
- 脾切除术与较低NRM相关(HR 0.64),但增加复发风险(HR 1.43),对OS无显著影响。
- 进展性疾病患者中,脾切除术相比脾≥15cm者生存改善(HR 0.44),NRM降低(HR 0.26)。
- 脾切除术使用率随时间下降(2000-2009年28.3% vs 2010-2017年14.1%)。
核心结论
- 脾切除术与较低的非复发死亡率相关但增加复发风险,对总生存无显著影响。
- 在进展性疾病患者中,脾切除术相比可触及脾长度≥15cm者生存改善,非复发死亡率显著降低且复发风险未显著增加。
- 研究提示巨脾对移植结局有潜在不利影响,支持进展性疾病伴巨脾患者行脾切除术。
研究设计与样本
- EBMT注册组回顾性分析,纳入1195例2000-2017年间接受异基因造血干细胞移植的骨髓纤维化患者。
- 移植预处理方案为氟达拉滨-白消安或氟达拉滨-美法仑。
- 202例(16.9%)患者行脾切除术,其使用率随时间下降(2000-2009年28.3% vs 2010-2017年14.1%)。
临床怎么用
- 对于进展性疾病伴巨脾(可触及脾长度≥15cm)的骨髓纤维化患者,脾切除术可能改善移植后生存。
- 脾切除术虽降低NRM但增加复发风险,临床决策需权衡利弊。
局限性
- 回顾性队列研究可能存在固有偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of spleen size and splenectomy for the prediction of post-allogeneic hematopoietic stem cell transplant (allo-HCT) outcome in myelofibrosis remains under debate. In EBMT registry, we identified a cohort of 1195 myelofibrosis patients transplanted between 2000-2017 after either fludarabine-busulfan or fludarabine-melphalan regimens. Overall, splenectomy was performed in 202 (16.9%) patients and its use decreased over time (28.3% in 2000-2009 vs 14.1% in 2010-2017 period). By multivariate analysis, splenectomy was associated with less NRM (HR 0.64, 95% CI 0.44-0.93, P = .018) but increased risk of relapse (HR 1.43, 95% CI 1.01-2.02, P = .042), with no significant impact on OS (HR 0.86, 95% CI 0.67-1.12, P = .274). However, in subset analysis comparing the impact of splenectomy vs specific spleen sizes, for patients with progressive disease, an improved survival was seen in splenectomised subjects compared to those patients with a palpable spleen length ≥ 15 cm (HR 0.44, 95% CI 0.28-0.69, P < .001), caused by a significant reduction in NRM (HR 0.26, 95% CI 0.14-0.49, P < .001), without significantly increased relapse risk (HR 1.47, 95% CI 0.87-2.49, P = .147). Overall, despite the possible biases typical of retrospective cohorts, this study highlights the potential detrimental effect of massive splenomegaly in transplant outcome and supports the role of splenectomy for myelofibrosis patients with progressive disease and large splenomegaly.
引用
- Polverelli N, Mauff K, Kröger N, et al. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). Am J Hematol. 2020. PMID: 33064301. doi:10.1002/ajh.26020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。